Selno, Anette Teo Hansen, Schlichtner, Stephanie, Yasinska, Inna M., Sakhnevych, Svetlana S., Fiedler, Walter, Wellbrock, Jasmin, Klenova, Elena, Pavlova, Ludmila, Gibbs, Bernhard F., Degen, Martin, and others. (2020) Transforming growth factor beta type 1 (TGF-B) and hypoxia-inducible factor 1 (HIF-1) transcription complex as master regulators of the immunosuppressive protein galectin-9 expression in human cancer and embryonic cells. Aging, 12 (23). pp. 23478-23496. E-ISSN 1945-4589. (doi:10.18632/aging.202343) (KAR id:85301)
PDF
Publisher pdf
Language: English
This work is licensed under a Creative Commons Attribution 4.0 International License.
|
|
Download this file (PDF/3MB) |
|
Request a format suitable for use with assistive technology e.g. a screenreader | |
Official URL: https://doi.org/10.18632/aging.202343 |
Abstract
Galectin-9 is one of the key proteins employed by a variety of human malignancies to suppress anti-cancer activities of cytotoxic lymphoid cells and thus escape immune surveillance. Human cancer cells in most cases express higher levels of galectin-9 compared to non-transformed cells. However, the biochemical mechanisms underlying this phenomenon remain unclear. Here we report for the first time that in human cancer as well as embryonic cells, the transcription factors hypoxia-inducible factor 1 (HIF-1) and activator protein 1 (AP-1) are involved in upregulation of transforming growth factor beta 1 (TGF-β1) expression, leading to activation of the transcription factor Smad3 through autocrine action. This process triggers upregulation of galectin-9 expression in both malignant (mainly in breast and colorectal cancer as well as acute myeloid leukaemia (AML)) and embryonic cells. The effect, however, was not observed in mature non-transformed human cells. TGF-β1-activated Smad3 therefore displays differential behaviour in human cancer and embryonic vs non-malignant cells. This study uncovered a self-supporting biochemical mechanism underlying high levels of galectin-9 expression operated by the human cancer and embryonic cells employed in our investigations. Our results suggest the possibility of using the TGF-β1 signalling pathway as a potential highly efficient target for cancer immunotherapy.
Item Type: | Article |
---|---|
DOI/Identification number: | 10.18632/aging.202343 |
Uncontrolled keywords: | galectin-9, immune escape, TGF-beta, HIF-1 |
Subjects: | R Medicine > RS Pharmacy and materia medica |
Divisions: | Divisions > Division of Natural Sciences > Kent and Medway Medical School |
Depositing User: | Vadim Sumbayev |
Date Deposited: | 04 Jan 2021 09:50 UTC |
Last Modified: | 10 Dec 2022 05:00 UTC |
Resource URI: | https://kar.kent.ac.uk/id/eprint/85301 (The current URI for this page, for reference purposes) |
- Link to SensusAccess
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):